In a trial involving sub-Saharan African women, intramuscular cabotegravir was superior to oral TDF/FTC for preventing HIV-1 infection.
Long-acting Injectable Cabotegravir for HIV-1 Prevention in Women Read More »
Lenacapavir susceptibility in the SC assay showed an inverse relationship between replication capacity and resistance. In Study 4072, all 29 participants receiving lenacapavir showed a robust virological response with no rebound. At baseline, no participant had resistance mutations to lenacapavir, and all had WT susceptibility to lenacapavir. Post-monotherapy analyses revealed the emergence of CA mutation
Long-acting injectable holds advantages over daily pills for pre-exposure prophylaxis against HIV, says ViiV executive.
Apretude, the New Tool in the HIV Prevention Toolkit Read More »
Ibalizumab, a recombinant humanized monoclonal antibody, represents the first novel agent for HIV-1 management in over a decade and is the first monoclonal antibody for the treatment of MDR HIV-1 infection in combination with other forms of antiretroviral therapy in heavily treatment-experienced adults who are failing their current antiretroviral regimen. Ibalizumab demonstrates a novel mechanism
Although both products for HIV prevention were generally safe, well tolerated, and effective, cabotegravir was superior to TDF-FTC in preventing HIV infection in women.
Cabotegravir for the prevention of HIV-1 in women Read More »
Based on the results of the ATLAS and FLAIR trials, Cabotegravir/Rilpivirine regimen once-monthly has shown equal effectivity to oral combination antiretroviral therapy (cART) in maintaining HIV-1 suppression in patients.
Cabotegravir/Rilpivirine: the last FDA-approved drug to treat HIV Read More »
With FDA Approval, the oral lead-in for the cabotegravir and rilpivirine long-acting HIV treatment (Cabenuva) is now optional. Clinical trial data showed similar safety and efficacy profiles for initiating the therapy with or without the oral lead-in.
Label Update for Cabotegravir and Rilpivirine Long-Acting HIV Treatment Read More »
Clinical review of Ibalizumab-uiyk (Trogarzo, Theratechnologies)
Pharmacist Medication Insights: Ibalizumab (Trogarzo) for HIV Read More »
Commentary on a study evaluating the safety and efficacy of bictegravir and cabotegravir in pregnancy.
Pre-exposure prophylaxis (PrEP), a potent medication for HIV prevention, shows promise for reducing HIV disparities. However, PrEP is not equitably utilized by all races and ethnicities in the USA. Its uptake is especially low among African Americans, who are disproportionately impacted by HIV. Understanding factors influencing low PrEP uptake among diverse priority groups of African
